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Pioneering endocrinologist and molecular biologist Donald Frederick Steiner, A. N. Pritzker Dis-
tinguished Service Professor of Medicine and Biochemistry andMolecular Biology at the University
of Chicago (Figure 1A), died on November 11, 2014 at the age of 84. “Very few scientists,” observed
Nobel Laureate Joseph L. Goldstein, MD, Chairman of the Department of Molecular Genetics at the
University of Texas (UT) Southwestern Medical Center, “can lay claim to original research that has
stood the test of time in both the biological and clinical arenas.” Steiner’s contributions meet this
dual standard. Dr. Steiner was also renowned for his mentorship of successive generations of leaders
in biochemistry and academic medicine.
For over five decades, Don Steiner maintained an active research laboratory, produced over
300 peer-reviewed papers, and made important contributions that advanced the fields of diabetes
research, protein precursor processing, peptide biology, and hormone evolution and action, a record
of productivity that has been matched by few scientists. His discovery of proinsulin in 1967 –
a milestone in peptide hormone biology – established proprotein biosynthesis and proteolytic
processing as an important field of study (1). Seminal pulse-chase studies of protein synthesis
in pancreatic β-cells (Figure 1B) deciphered the biosynthetic pathway of proinsulin (Figure 1C),
leading to determination of its structure (Figure 1D).
Following the discovery of insulin in 1921 by Frederick G. Banting and Charles H. Best in
the laboratory of John J. R. Macleod (and its further purification in collaboration with James B.
Collip), the clinical importance and availability of this hormone made it an attractive target for
biochemical studies. This early era of discovery culminated in the complete amino-acid sequence
determination of the mature hormone by Frederick Sanger in 1955; these Nobel-recognized studies
showed that insulin is composed of two peptide chains (designated A and B) linked by disulfide
bonds. However, the primary sequence immediately raised a fundamental problem in biosynthesis:
were the two chains synthesized separately and recombined post-translationally, or was a precursor
(“proinsulin”) synthesized and proteolytically cleaved to form the mature hormone? This question
was put into sharp relief following international efforts in the 1960s to synthesize insulin through
chemical methods. In preparations of synthetic insulin (with purity amenable to crystallization)
independently obtained in the laboratories of Panayotis G. Katsoyannis (University of Pittsburgh),
Niu Jingyi and colleagues (Academia Sinica Institute of Biochemistry, Shanghai), and Helmut Zahn
(GermanWool Research Institute in Aachen; DeutschesWollforschungsinstitut), the final synthetic
step was remarkable for its inefficiency: combination of the separate A- and B-peptide chains to
achieve specific disulfide pairing. Indeed, the structure, stability, and activity of insulin requires
formation of three such bridges, two between chains (cystines A7–B7 and A20–B19) and one within
the A chain (cysteine A6–A11) as illustrated in Figure 1D (gold boxes).
To solve this problem, Steiner adopted a synergistic approach that exemplified the productive
potential of a collaboration between clinical investigation and basic science: a surgical speci-
men obtained from a patient with a pancreatic β-cell tumor (insulinoma) was studied in con-
cert with an animal model (rat islet extracts), and then frontier biochemical methods (chro-
matographic resolution of the protein products of pulse–chase assays) were used to identify
and characterize proinsulin (illustrated in Figure 1B). “This finding was a bolt from the blue,”
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FIGURE 1 | Discovery of proinsulin. (A) Steiner in his laboratory at the
University of Chicago in the mid-1970s. Gel-filtration column chromatography
enabled separation of proinsulin, insulin, and C-peptide. (B) Chromatograms
documenting the transformation of proinsulin to insulin in isolated islets of
Langerhans as described in the landmark paper of 1967 (1). Top panel, elution
pattern of 3H-Leu labeled acid-alcohol soluble protein extracted after
incubation for 40min. Middle two panels, transfer of radioactivity from peak b
(proinsulin) to c (insulin) during subsequent 140min in presence, respectively,
of cycloheximide or 100-fold excess of unlabeled l-leucine. Bottom panel,
pattern of radioactivity after 200min incubation without intervention. Optical
density (vertical axis at left) pertains to added bovine insulin as control.
Chromtography employed G-50 Sephadex. (C,D) Biosynthesis of proinsulin.
(C) Pathway begins with preproinsulin (top): signal peptide (gray), B-domain
(blue), dibasic BC junction (green), C-domain (black), dibasic CA junction
(green), and A-domain (red). Specific disulfide pairing in the ER yields native
proinsulin (middle panels). BC and CA cleavage (mediated by prohormone
convertases PC1 and PC2) releases insulin and C-peptide (bottom).
(D) Solution structure of proinsulin: insulin-like moiety and disordered
connecting peptide (black line). A- and B-domains are shown in red and blue,
respectively; C-domain contains a nascent α-helical turn near the CA junction.
Cystines are labeled in yellow boxes. This figure was obtained from Weiss (2)
with permission of the author.
remembered Katsoyannis, “as we had been operating under the
assumption that the cellular biosynthesis of insulin would mir-
ror its chemical synthesis.” It is a further tribute to Steiner’s
insight as a physician-scientist that he immediately recognized
the clinical utility of proinsulin and the C-peptide (derived
from the peptide segment in the proinsulin molecule that
connects its B and A domains), leading to the development
(with Arthur H. Rubenstein) of radioimmunoassays for these
molecules. The C-peptide assay is still in use to assess resid-
ual β-cell function in patients and track its preservation or
decline in the natural history of both type 1 and type 2 diabetes
mellitus.
In subsequent years, Steiner both continued to character-
ize proinsulin and expanded his research to other areas which,
although insulin-focused, utilized cutting-edge techniques in
molecular biology, in part developed in-house. Together with
student Susan Terris, Steiner was thus the first to show that insulin
clearance in the blood is mediated by its binding to the insulin
receptor. Further, the Steiner laboratory was among the first to
clone and characterize the convertase enzymes that process pro-
proteins. As a physician-scientist, Steiner also helped to identify
a new class of monogenic diabetes syndromes due to mutations
in the insulin gene, a program of research first led at the protein
level by the late Howard S Tager1 and enriched by the clinical
insight of Rubenstein. Steiner’s interest in monogenic diabetes
syndromes also led (in collaboration with colleague Graeme I.
Bell) to the characterization of clinical mutations in the insulin
receptor gene. Recent studies by the Chicago team of Bell, Steiner,
and Louis H. Philipson extended this program to identify a novel
class of mutations that perturb the nascent folding of proinsulin, a
major molecular mechanism of β-cell dysfunction in permanent
neonatal-onset diabetes.
Steiner combined his long-term interest in diabetes-related
molecular genetics with foundational studies in evolutionary biol-
ogy. The sequence, structure, and function of insulin-like proteins
provided a model for probing the origins, evolution, and diver-
gence of a gene family. With one of the present authors (Shu Jin
Chan), Steiner presented evidence that insulin and related insulin-
like growth factors evolved from a common ancestral gene early
in chordate evolution. This work anticipated the discovery by
several laboratories of an insulin-related superfamily of protein
1Tager was a post-doctoral fellow with Steiner from 1971 to 1973. He returned to
the University of Chicago in 1974 as an Assistant Professor of Biochemistry and
Molecular Biology and rapidly rose through the ranks. At the time of his death in
1994, Tager was Louis Block Professor and Department Chair.
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folds in metazoans (including fruit flies and nematodes) whose
rich biology continues to be a source of discovery.
Steiner kept in his office a three-dimensional atomic model
of the insulin molecule (Figure 2A). Evocative in its artistry,
this model was a gift of the late Nobel Laureate Dorothy C.
Hodgkin (inset at upper right in Figure 2A) whose Oxford labora-
tory’s pioneering crystallographic analysis of the insulin hexamer
came to fruition just after the discovery of proinsulin.2 “Don
made a very original and generous contribution to our science,”
reflected Sir Thomas L. Blundell (Sir William Dunn, Professor of
Biochemistry at Cambridge University), at that time a graduate
student. “The discovery of proinsulin had a huge influence on
the way that the Hodgkin group in the 1960s – Guy Dodson,
Eleanor Dodson, [Mamannamana] Vijayan, and me – thought
about insulin as we sought to understand the relationship of
sequence, structure, folding, and function.” This model depicted
insulin as a monomer (as extracted from the crystallographic
hexamer) and so highlighted the central and still elusive question
of how themonomeric hormone binds to and activates the insulin
receptor, which is a homodimer (Figure 2B). To address this
question, Steiner was a key member of an international team
(also involving the present authors) that recently obtained crystal
structures of insulin bound to fragments of the insulin receptor
(3, 4). “I have very fond memories of my conversations and
interactions with him over the past 15 years as we began to tease
out the nature of the insulin/receptor interaction,” remembered
ColinWard [founder of the receptor crystallographic group at the
Commonwealth Scientific and Industrial Research Organization
(CSIRO) in Melbourne, Australia]. “What a true inspiration he
was with his enthusiasm for science to the end.”
Critical to the recent crystallographic efforts was Steiner’s pre-
scient identification in 1994 of a novel hormone-binding element
within the insert domain (labeled “Ins” in Figure 2B) at the
extreme C-terminus of the receptor α subunit (highlighted in
red). This conserved element, designated αCT, is shared by the
Type 1 IGF receptor but not, to our knowledge, other classes
of receptor tyrosine kinases. The tandem motif of αCT (red α-
helix in Figure 2C) and the N-terminal leucine-rich domain of
the receptor α subunit (L1 domain; green in Figure 2C) defines
the primary hormone-binding site of the ectodomain (boxed).
The identification of αCT by residue-specific hormone-receptor
photo-crosslinking by the collaborating laboratories of Steiner
and Katsoyannis represented a tour de force of synthetic pep-
tide chemistry and analytical biochemistry (5). “Methods for the
total chemical synthesis of insulin,” recalled Katsoyannis, “enabled
preparation of unique research reagents to probe photo-contacts
2Eleanor Dodson (Professor of Chemistry at the University of York, York, UK)
recalls that the model was a gift from Hodgkin. In the years after the discovery of
proinsulin and determination of the insulin crystal structure, Steiner, Hodgkin, and
Dorothy’s former students (Guy and Eleanor Dodson at York; and John F. Cutfield
and Sue M. Cutfield, University of Otago, Dunedin, NZ) regularly visited each
other’s laboratories. “Donwas a very good friend as well as a great scientist,” Eleanor
Dodson shared. “We had some very happy times with him.” Through the Dodsons,
this network of interactions was extended to Martin Karplus (Theodore William
Richards, Professor of Chemistry Emeritus at Harvard University and recipient of
the 2013 Nobel Prize in Chemistry) who encouraged studies of insulin by NMR
spectroscopy and molecular-dynamics simulations.
FIGURE 2 | An international structural team. (A) Steiner’s office at the
University of Chicago with Oxford model of insulin in its classical
crystallographic conformation (foreground). Inset at top right, Hodgkin and
Steiner with matching molecular models. (B,C) Next structural frontier: the
tandem hormone-binding site of the insulin receptor. (B) Domain organization
of the disulfide-bridged αβ monomer (left) and ectodomain (right), comprising
(αβ
∆
)2 dimer wherein β∆ represents a fragment lacking transmembrane
α-helix and intracellular domains. L1 and αCT are highlighted in green and red
(left), respectively. Domains (gray scale) are otherwise designated
cysteine-rich (CR), second Leu-rich repeat domain (L2), type III
fibronectin-homology domains (Fn1-3), insert domain (Ins, split between
C-terminus of α subunit (bottom) and N-terminus of β subunit (top)),
transmembrane and juxtamembrane regions (TM/JM), tyrosine kinase (TK),
and C-terminal segment (αCT; 704-FEDYLHNVVFV-715; α-helix bold).
Disulfide bridges are shown as horizontal lines. (C) Crystal structure of
ectodomain. One αβ
∆
protomer is shown as a ribbon; the other as sticks. L1
and αCT in each protomer are highlighted in green and red. Electron density
of ID-N is incomplete. This figure was adopted with permission from Whittaker
(6). Coordinates of the ectodomain of the insulin receptor were obtained from
Protein Databank entry 3LOH as described (7).
by individual residues. This extended photo-chemistry from small
peptides to a globular hormone3.”
To achieve these results over five decades, Steiner strove to
create a laboratory that was structured but also allowed scien-
tific freedom for the training of physician-scientists and basic
investigators. “The atmosphere in his laboratory was pleasant,
but the planning, execution, and evaluation of experiments was
rigorous andmeticulous,” remembered former fellows Rubenstein
3Katsoyannis emphasized the complementary contributions of several laborato-
ries to the development of synthetic (or semi-synthetic) insulin photo-chemistry,
including D. Brandenburg, S. E. Shoelson, and the late C. C. Yip.
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(Dean Emeritus of the University of Pennsylvania School of
Medicine) andKenneth S Polonsky (Dean of the Pritzker School of
Medicine at the University of Chicago). “He spent hours worrying
about unexpected results and repeated experiments numerous
times before being satisfied. We all felt part of his team and when
new discoveries were made, we all shared in the joy of the science
and celebrated together.” During the initial characterization of
proinsulin, however, Steiner felt constrained to limit projects that
the group could pursue. “It was one of the hardest things that I
ever had to do,” he said to one of the present authors (Shu Jin
Chan), “since I’ve always felt that students should be free to explore
their creative ideas.” It was this focus at a seminal time in the
history of molecular endocrinology that enabled the paradigm of
prohormone processing to be established.
In recognition of his scientific achievements, Steiner received
numerous awards and prizes, including the Gairdner Award
(1971), Diaz-Cristobal Award (1973), Banting Medal (1976),
Borden Medal (1980), Wolf Foundation Prize (1985), Fred C.
Koch Award (1990), and Manpei Suzuki Prize (2009). He also
received honorary degrees from the University of Umea (Swe-
den), University of Illinois (Chicago), Rheinisch-Westfalische
Technische Hochschule (Germany), University of Uppsala (Swe-
den), Mount Sinai School of Medicine (New York), and Uni-
versity of Copenhagen (Denmark). Steiner was for many years
a member of the Editorial Board of the Journal of Bio-
logical Chemistry and a founding Associate Editor of this
journal.
Don Steiner was born in 1930 in Lima, Ohio and in 1952
received a BS in Chemistry and Zoology from the University
of Cincinnati. In 1956, he obtained an MS in Biochemistry
and MD from the University of Chicago. Following an intern-
ship at King County Hospital (Seattle) and residency and post-
doctoral training at the University of Washington, Steiner joined
the Department of Biochemistry at Chicago in 1960. Promoted
to professor in 1968 and department chair in 1973, he was
a Senior Investigator in the Howard Hughes Medical Institute
(HHMI) from 1985 to 2006. Steiner was also Director of the Uni-
versity of Chicago Diabetes-Endocrinology Center (1974–1978)
and for 40 years served as the leader or coleader of the Uni-
versity’s NIH-designated Diabetes Research and Training Cen-
ter (DRTC). Steiner was a member of the American Academy
of Arts and Sciences (elected in 1972), the National Academy
of Sciences (1973), and the American Philosophical Society
(2004).
Steiner’s pioneering dissection of the molecular mechanisms of
insulin biosynthesis provided broad insight into cell biology and
protein evolution. “Fifty years ago,” concluded Goldstein, “Don
Steiner discovered that insulin in the blood is derived from a larger
precursor molecule. This exceptionally original work profoundly
influenced the thinking of biologists, leading to the concept of
proteolytic processing as a mechanism for generating regulatory
peptides.” Yet, his legacy extends beyond even these landmark
investigations. “Don Steiner had a broad and profound impact
as a result not only of his groundbreaking scientific discoveries,”
remembers Polonsky, “but also because of his generosity in help-
ing colleagues, collaborators, and particularly students and other
trainees to raise the level of their science.” We shall miss him both
as a brilliant scientist and colleague of profound humanity.
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